Inbrija
·
- Prescription status not stated
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Levodopa
- Made by
- Merz Therapeutics GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Merz Therapeutics GmbH |
|---|---|
| Active substance | Levodopa |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Classification | N04BA01 · Pain, sleep, mood, epilepsy and the brain |
| Authorised on | 2019-09-19 |
| Last updated by the regulator | 2025-12-09 |
| EMA product number | EMEA/H/C/004786 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).